– CHINA, Hong Kong – HUTCHMED (China) Limited (Nasdaq: HCM / LON: HCM / HKEX: 13) today announced the appointment of Dr. Renu Bhatia to its Board as an Independent Non-Executive Director effect from May 13, 2024.
“I would like to extend a warm welcome to Dr Bhatia to the Company. We believe that her expertise in the healthcare, finance and fintech sectors will bring fresh perspective and provide constructive insight to the Board.” said Board Chairman, Simon To.
Dr. Renu Bhatia will also join the Technical Committee.
About Dr. Renu Bhatia
Dr. Renu Bhatia, a licensed physician, has over 25 years of experience in the healthcare, finance fintech, and regulatory sectors. She is an experienced board director and chair, with a healthcare and financial services background in investment banking, asset management, venture capital, and compliance. The Board of HUTCHMED is of the view that Dr Bhatia will further enhance the skill set, expertise,e and knowledge base of the Board as a whole.
Dr. Renu Bhatia is the chairman and co-founder of Opharmic Technology (HK) Ltd, a company focusing on the development of ultrasound technology for non-invasive drug delivery to the eyes. She is also co-founder of Asia Fintech Angels which invested in early-stage fintech companies. In addition, Dr. Bhatia is an independent non-executive director of Overstone Associates Limited, a leading UK-based data science provider to financial institutions focused on the art industry.
Dr Bhatia is the chairman of the Listing Committee of The Stock Exchange of Hong Kong Limited. She also holds positions in public service including membership of the Business Professional Federation Healthcare Committee and the Cyberport Entrepreneurship Centre Advisory Group, and acting as an assessor for the Hong Kong Enterprise Support Scheme Assessment Panel of the Innovation and Technology Fund. Dr Bhatia started her career in finance at Goldman Sachs and HSBC Asset Management.
Dr Bhatia is a Doctor of Medicine (MBBS) from the University of London and holds a Master of Business Administration degree from Yale University, and a Postgraduate Diploma in Therapeutics and Medicine from The University of Hong Kong.
About HUTCHMED
HUTCHMED is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development,t and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since its inception, HUTCHMED has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S.
SOURCE: https://www.hutch-med.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
